CLAIMS

What is claimed is:

1. A compound, including enantiomers, stereoisomers and tautomers thereof, or pharmaceutically acceptable salts or solvates of said compound, with said compound having the general structure shown in Formula I:



Formula I

M is a moiety having a general structure shown in Formula II or III:



II



III

where k = 0 or 1, n = 0-5, and p = q = 0, 1 or 2 with the proviso that when M is Formula III, R^3 is absent;

V is a moiety selected from the group consisting of C_1-C_8 alkyl; $-(CH_2)_x-A-(CH_2)_y-$; and $-(CH_2)_c-A-(CH_2)_m-C(O)-N(R^7)-(CH_2)_d-$, where A is -O-, $-S(O)_r-$, and $-NR^7-$; m = 0, 1, 2 or 3; x is a whole number in the range 2-8, y is a whole number in the range 1-5; c is a whole number in the range 2-4; and r= 0, 1 or 2; d is a number in the range 0-5;

X and Y are independently selected from the group consisting of N, CH, and N(O);

Z is selected from the group consisting of N, CH and N(O);

R^1 and R^2 may each number 1-4 and are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halogen, polyhalolower alkyl, polyhalolower alkoxy, -OH, CN, NO_2, or $COOR^8$;

R^3 is selected from hydrogen, lower alkyl, lower alkoxy, hydroxyl, with the proviso that when n and k are both 0, then R^3 is not -OH or alkoxy;

R^4 is selected from the group consisting of hydrogen, lower alkyl, polyhalolower alkyl or -OH; and

R^7 and R^8 are independently selected from hydrogen, lower alkyl, substituted or unsubstituted phenyl; and substituted or unsubstituted benzyl.

2. The compound of claim 1, wherein R^4 is H.

3. The compound of claim 2, wherein R^1 and R^2 are independently selected from H, halogen, or polyhalolower alkyl.

4. The compound of claim 1, wherein M is:



and p and q are independently 0 or 1.

5. The compound of claim 1, wherein M is:



and p = q = 1.

6. The compound of claim 4, wherein R^4 is H; $R^1 = R^2 = H$, halogen, hydroxy or alkoxy; and R^3 is H or lower alkyl.

7. The compound of Claim 6, wherein V = $C_1 - C_8$ alkyl.

8. The compound of claim 5, wherein R^4 is H; and $R^1 = R^2 = H$, halogen, hydroxy or alkoxy.

9. The compound of Claim 8, wherein V is $C_1 - C_8$ alkyl.

10. A pharmaceutical composition comprising as an active ingredient a compound of claim 1.

11. A pharmaceutical composition for use in treating inflammation, allergy, allergic rhinitis, nasal congestion, diseases of the GI-tract, cardiovascular

disease, or disturbances of the central nervous system as well as allergy-induced airway responses, nasal congestion and obesity, said composition comprising as an active ingredient a compound of claim 1.

12. The pharmaceutical composition of claim 10 additionally comprising a pharmaceutically acceptable carrier.

13. A method of treating inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 1.

14. The use of a compound of claim 1 for the manufacture of a medicament for the treatment of inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity.

15. A method of preparing a pharmaceutical composition for treating inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said method comprising bringing into intimate contact a compound of claim 1 and a pharmaceutically acceptable carrier.

16. A compound exhibiting H_3 antagonist activity, including enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:











Sub AS

17. A compound exhibiting both H_1 and H_3 antagonist activity, including enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:





Sub A5



















18. A pharmaceutical composition for treating inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said composition comprising therapeutically effective amount of a compound of claim 16 or claim 17 and a pharmaceutically acceptable carrier.